While Pfizer Inc. certainly has its eye on the near-term revenue stream coming from Seagen Inc. ’s four commercial drugs with its proposed $43bn acquisition of the Seattle-based cancer drug developer, a key component of the deal is Seagen’s next-generation antibody-drug conjugates (ADCs) and future potential for combinations.
What Seagen’s Pipeline Will Bring To Pfizer
Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.
More from R&D
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
More from Scrip
• By
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.